Gan & Lee Pharmaceuticals Future Growth
Future criteria checks 5/6
Gan & Lee Pharmaceuticals is forecast to grow earnings and revenue by 68.1% and 25.9% per annum respectively. EPS is expected to grow by 67.7% per annum. Return on equity is forecast to be 8.5% in 3 years.
Key information
68.1%
Earnings growth rate
67.7%
EPS growth rate
Biotechs earnings growth | 34.3% |
Revenue growth rate | 25.9% |
Future return on equity | 8.5% |
Analyst coverage | Low |
Last updated | 31 Jan 2024 |
Recent future growth updates
No updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2025 | 4,230 | 1,165 | N/A | 1,198 | 3 |
12/31/2024 | 3,278 | 654 | N/A | 663 | 3 |
12/31/2023 | 2,585 | 322 | N/A | 264 | 3 |
9/30/2023 | 2,381 | 241 | -859 | -241 | N/A |
6/30/2023 | 2,107 | -108 | -795 | -43 | N/A |
3/31/2023 | 1,580 | -504 | -920 | 47 | N/A |
12/31/2022 | 1,712 | -440 | -687 | 297 | N/A |
9/30/2022 | 2,346 | 168 | -108 | 757 | N/A |
6/30/2022 | 2,971 | 882 | 156 | 913 | N/A |
3/31/2022 | 3,753 | 1,376 | 490 | 1,102 | N/A |
12/31/2021 | 3,612 | 1,453 | 386 | 1,078 | N/A |
9/30/2021 | 3,673 | 1,416 | 320 | 1,047 | N/A |
6/30/2021 | 3,630 | 1,296 | 321 | 1,067 | N/A |
3/31/2021 | 3,441 | 1,298 | 443 | 1,216 | N/A |
12/31/2020 | 3,362 | 1,231 | 659 | 1,241 | N/A |
9/30/2020 | 3,234 | 1,192 | 824 | 1,318 | N/A |
6/30/2020 | 3,144 | 1,207 | 996 | 1,401 | N/A |
3/31/2020 | 2,937 | 1,193 | 804 | 1,103 | N/A |
12/31/2019 | 2,895 | 1,167 | 751 | 1,158 | N/A |
12/31/2018 | 2,387 | 934 | -95 | 418 | N/A |
12/31/2017 | 2,371 | 1,080 | 519 | 950 | N/A |
12/31/2016 | 1,771 | 770 | N/A | 686 | N/A |
12/31/2015 | 1,220 | 447 | N/A | 502 | N/A |
12/31/2014 | 927 | 305 | N/A | 296 | N/A |
12/31/2013 | 693 | 205 | N/A | 167 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 603087's forecast earnings growth (68.1% per year) is above the savings rate (2.9%).
Earnings vs Market: 603087's earnings (68.1% per year) are forecast to grow faster than the CN market (24.5% per year).
High Growth Earnings: 603087's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 603087's revenue (25.9% per year) is forecast to grow faster than the CN market (14.6% per year).
High Growth Revenue: 603087's revenue (25.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 603087's Return on Equity is forecast to be low in 3 years time (8.5%).